Back to Journals » Therapeutics and Clinical Risk Management » Volume 3 » Issue 4

Review of thalidomide in the treatment of newly diagnosed multiple myeloma

Authors Federica Cavallo, Mario Boccadoro, Antonio Palumbo

Published 15 September 2007 Volume 2007:3(4) Pages 543—552

Federica Cavallo, Mario Boccadoro, Antonio Palumbo

Divisione di Ematologia dell’Universita’ di Torino, Azienda Ospedaliera San Giovanni Battista, 10126 Torino, Italy

Abstract: The role of thalidomide has been well established in the setting of relapsed or refractory multiple myeloma (MM). More recently, studies have been focused on upfront induction therapy. In newly diagnosed MM patients, thalidomide improved the response rates and the event-free survival induced by both high-dose and conventional chemotherapy regimens. The effect on survival needs to be further investigated. The efficacy of this drug is counterbalanced by a significant rate of both acute and long-term toxicities. Thus best timing of initiation, dosing schemes and duration of therapy is still unclear. Evidence is now emerging that clinical response can be achieved also at lower doses with minimal long term toxicity.

Keywords: Multiple myeloma, thalidomide, front-line therapy

Download Article [PDF] 

Readers of this article also read:

Paclitaxel attenuates renal interstitial fibroblast activation and interstitial fibrosis by inhibiting STAT3 signaling

Zhang L, Xu X, Yang R, Chen J, Wang S, Yang JQ, Xiang X, He Z, Zhao Y, Dong Z, Zhang D

Drug Design, Development and Therapy 2015, 9:2139-2148

Published Date: 15 April 2015

Sequential release of salidroside and paeonol from a nanosphere-hydrogel system inhibits ultraviolet B-induced melanogenesis in guinea pig skin

Peng LH, Xu SY, Shan YH, Wei W, Liu S, Zhang CZ, Wu JH, Liang WQ, Gao JQ

International Journal of Nanomedicine 2014, 9:1897-1908

Published Date: 16 April 2014

Lysine-functionalized nanodiamonds: synthesis, physiochemical characterization, and nucleic acid binding studies

Kaur R, Chitanda JM, Michel D, Maley J, Borondics F, Yang P, Verrall RE, Badea I

International Journal of Nanomedicine 2012, 7:3851-3866

Published Date: 19 July 2012

Update on the treatment of ankylosing spondylitis

Walter P Maksymowych

Therapeutics and Clinical Risk Management 2007, 3:1125-1133

Published Date: 15 January 2008

Pharmacological causes of hyperprolactinemia

Daria La Torre, Alberto Falorni

Therapeutics and Clinical Risk Management 2007, 3:929-951

Published Date: 15 November 2007

A review of rabeprazole in the treatment of acid-related diseases

Fabio Pace, Stefano Pallotta, Stefania Casalini, Gabriele Bianchi Porro

Therapeutics and Clinical Risk Management 2007, 3:363-379

Published Date: 15 July 2007

Effect of patient-specific factors on weekly warfarin dose

Heather P Whitley, Joli D Fermo, Elinor CG Chumney, Walter Adam Brzezinski

Therapeutics and Clinical Risk Management 2007, 3:499-504

Published Date: 15 July 2007

Acne phototherapy with a 1450-nm diode laser: an open study

Natusko Konishi, Hideki Endo, Naoki Oiso, Shigeru Kawara, Akira Kawada

Therapeutics and Clinical Risk Management 2007, 3:205-209

Published Date: 15 March 2007